Murrysville, Pa.
The “problem sleeper” patient may be a dozing giant for HME.
That's something Respironics is banking on as the sleep products manufacturer expands its development efforts beyond the traditional obstructive sleep apnea (OSA) market. The company made the announcement during a press briefing at Medtrade in Orlando, Fla.
Respironics recently formed its Sleep Wellness Ventures business unit to focus on products for disorders outside OSA.
“We think there's a tremendous and growing opportunity,” said President and CEO John Miclot.
“We surveyed a group of [healthy] individuals, and over half of them said they suffered from sleep problems that affected their quality of life. So we believe half the population is a potential market opportunity.”
The business unit is currently studying product possibilities for patients suffering from sleep rhythms and phase-shift disorders, along with sleep onset and sleep maintenance problems, Miclot said, adding that the unit is also studying medical needs within the mild-to-moderate OSA population.
